Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Sees Large Increase in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLAW) saw a significant increase in short interest in January. As of January 15th, there was short interest totaling 17,060 shares, an increase of 189.0% from the December 31st total of 5,904 shares. Based on an average daily volume of 3,229 shares, the days-to-cover ratio is presently 5.3 days. Based on an average daily volume of 3,229 shares, the days-to-cover ratio is presently 5.3 days.

Estrella Immunopharma Stock Performance

Shares of ESLAW stock opened at $0.06 on Thursday. Estrella Immunopharma has a fifty-two week low of $0.03 and a fifty-two week high of $0.24. The business has a fifty day simple moving average of $0.07 and a 200-day simple moving average of $0.07.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.